SWKHL on Nasdaq
SWK Holdings Corp
American miscellaneous business credit institution company. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with STANDARD PREMIUM FINANCE HOLDINGS, INC. or Troops, Inc. /Cayman Islands/, or pick any stock.
- TickerSWKHL on Nasdaq1
- IndustryMiscellaneous Business Credit Institution1
- HeadquartersDallas, Texas1
- Incorporated inDE2
- Business address5956 Sherry Lane, Suite 650, Dallas, Tx 752252
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
In addition to historical information, this Annual Report on Form 10-K (“Annual Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. From time to time, we may also provide oral or written forward-looking statements in other materials we release to the public. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. The forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections about our business and industry, and our beliefs and assumptions, and include, but are not limited to, statements under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Words such as “anticipate,…3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development6¢$1.6M
- Income tax94¢$22.6M
Out of $2.2M in revenue.4 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending2¢$512.0K
- Share buybacks11¢$3.1M
- Kept or used elsewhere87¢$23.7M
Out of $27.3M of cash from operations.4
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Finance receivable interest income, including fees | $38.4M | $40.8M |
| Pharmaceutical development | $2.2M | $3.6M |
| Other | $865.0K | $584.0K |
| Total revenues | $41.5M | $45.0M |
| Provision for (benefit from) credit losses | -$924.0K | $12.8M |
| Loss on impairment | $641.0K | $5.8M |
| Loss on disposal of inventory | $314.0K | $0 |
| Interest expense | $4.8M | $4.7M |
| Pharmaceutical manufacturing, research and development expense | $1.6M | $2.2M |
| Change in fair value of acquisition-related contingent consideration | $0 | -$4.9M |
| Depreciation and amortization expense | $40.0K | $1.4M |
| General and administrative expense | $14.8M | $11.5M |
| Income from operations | $20.3M | $11.6M |
| Unrealized net gain on warrants | $775.0K | $2.4M |
| Net gain on exercise and cancellation of warrants | $0 | $445.0K |
| Loss on sale of assets | -$82.0K | $0 |
| Gain on sale of business | $1.6M | $0 |
| Net loss on marketable investments | -$384.0K | -$266.0K |
| Realized gain on early payment of finance receivables | $1.7M | $1.1M |
| Gain (loss) on revaluation of finance receivables | -$3.7M | $2.5M |
| Realized and unrealized foreign currency transaction gains (losses) | -$71.0K | $641.0K |
| Income before income tax expense | $20.1M | $18.4M |
| Income tax expense | $22.6M | $4.9M |
| Net income (loss) | -$2.5M | $13.5M |
| Basic (in dollars per share) | -$0.21 | $1.09 |
| Diluted (in dollars per share) | -$0.21 | $1.09 |
| Basic (in shares) | 12.2M shares | 12.4M shares |
| Diluted (in shares) | 12.2M shares | 12.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $42.8M | $5.9M | |
| Interest, accounts receivable, and other receivables | $3.9M | $5.8M | |
| Assets held for sale, net (Note 6) | $0 | $6.4M | |
| Other current assets | $163.0K | $2.1M | |
| Total current assets | $46.8M | $20.3M | |
| Finance receivables, net of allowance for credit losses of $7,278 and $11,249 as of December 31, 2025 and 2024, respectively | $218.6M | $277.8M | |
| Collateral on foreign currency forward contract | $0 | $2.8M | |
| Marketable investments | $184.0K | $580.0K | |
| Deferred tax assets, net | $912.0K | $23.5M | |
| Warrant assets | $5.9M | $4.4M | $1.8M |
| Other non-current assets, net | $0 | $3.0M | |
| Total assets | $272.4M | $332.2M | |
| Accounts payable and accrued liabilities | $5.0M | $2.8M | |
| Liabilities held for sale, net (Note 6) | $0 | $1.3M | |
| Deferred income | $0 | $1.5M | |
| Total current liabilities | $5.0M | $5.6M | |
| Unsecured senior notes, net | $32.1M | $31.4M | |
| Revolving credit facility | $0 | $6.2M | |
| Other non-current liabilities | $240.0K | $335.0K | |
| Total liabilities | $37.3M | $43.5M | |
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.001 par value; 250,000,000 shares authorized; 12,095,979 and 12,213,599 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $12.0K | $12.0K | |
| Additional paid-in capital | $4.4B | $4.4B | |
| Accumulated deficit | -$4.2B | -$4.1B | |
| Total stockholders' equity | $235.1M | $288.7M | $280.3M |
| Total liabilities and stockholders' equity | $272.4M | $332.2M | |
| Financing receivable, allowance for credit loss excluding accrued interest | $7.3M | $11.2M | $13.9M |
| Preferred stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | |
| Common stock, shares, issued (in shares) | 12.1M shares | 12.2M shares | |
| Common stock, shares, outstanding (in shares) | 12.1M shares | 12.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $42.8M | $5.9M | |
| Interest, accounts receivable, and other receivables | $3.9M | $5.8M | |
| Assets held for sale, net (Note 6) | $0 | $6.4M | |
| Other current assets | $163.0K | $2.1M | |
| Total current assets | $46.8M | $20.3M | |
| Finance receivables, net of allowance for credit losses of $7,278 and $11,249 as of December 31, 2025 and 2024, respectively | $218.6M | $277.8M | |
| Collateral on foreign currency forward contract | $0 | $2.8M | |
| Marketable investments | $184.0K | $580.0K | |
| Deferred tax assets, net | $912.0K | $23.5M | |
| Warrant assets | $5.9M | $4.4M | $1.8M |
| Other non-current assets, net | $0 | $3.0M | |
| Total assets | $272.4M | $332.2M | |
| Accounts payable and accrued liabilities | $5.0M | $2.8M | |
| Liabilities held for sale, net (Note 6) | $0 | $1.3M | |
| Deferred income | $0 | $1.5M | |
| Total current liabilities | $5.0M | $5.6M | |
| Unsecured senior notes, net | $32.1M | $31.4M | |
| Revolving credit facility | $0 | $6.2M | |
| Other non-current liabilities | $240.0K | $335.0K | |
| Total liabilities | $37.3M | $43.5M | |
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.001 par value; 250,000,000 shares authorized; 12,095,979 and 12,213,599 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $12.0K | $12.0K | |
| Additional paid-in capital | $4.4B | $4.4B | |
| Accumulated deficit | -$4.2B | -$4.1B | |
| Total stockholders' equity | $235.1M | $288.7M | $280.3M |
| Total liabilities and stockholders' equity | $272.4M | $332.2M | |
| Financing receivable, allowance for credit loss excluding accrued interest | $7.3M | $11.2M | $13.9M |
| Preferred stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 5.0M shares | 5.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par or stated value per share (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | |
| Common stock, shares, issued (in shares) | 12.1M shares | 12.2M shares | |
| Common stock, shares, outstanding (in shares) | 12.1M shares | 12.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) | -$2.5M | $13.5M |
| Provision for (benefit from) credit losses | -$695.0K | $12.8M |
| Loss on sale of assets | $82.0K | $0 |
| Loss on impairment | $641.0K | $5.8M |
| Right-of-use amortization | $143.0K | $415.0K |
| Amortization of debt issuance costs | $1.4M | $1.1M |
| Deferred income taxes, net | $22.6M | $4.8M |
| Unrealized net gain on warrants | -$775.0K | -$2.4M |
| Loss on disposal of inventory | $314.0K | $0 |
| Net gain on exercise and cancellation of warrants | $0 | -$445.0K |
| Gain on sale of business | -$1.5M | $0 |
| Change in fair value of acquisition-related contingent consideration | $0 | -$4.9M |
| Loss (gain) on revaluation of finance receivables | $3.7M | -$2.5M |
| Foreign currency transaction gains | -$681.0K | -$1.4M |
| Loss on marketable investments | $384.0K | $266.0K |
| Loan discount amortization and fee accretion | -$2.2M | -$3.9M |
| Interest paid-in-kind | -$1.8M | -$2.8M |
| Stock-based compensation | $1.2M | $944.0K |
| Depreciation and amortization expense | $40.0K | $1.4M |
| Interest, accounts receivable and other receivables | $1.9M | -$1.1M |
| Derivative assets and liabilities, net | $915.0K | $1.2M |
| Collateral on foreign currency forward contract | $2.8M | $0 |
| Other assets, net | $1.3M | $199.0K |
| Accounts payable, accrued expenses, and other non-current liabilities | $1.6M | -$1.3M |
| Deferred income | -$1.5M | $1.5M |
| Net cash provided by operating activities | $27.3M | $23.0M |
| Proceeds from sale of property and equipment | $110.0K | $0 |
| Settlement of foreign currency forward contract | $1.6M | $0 |
| Proceeds from sale of assets and liabilities held for sale | $6.8M | $0 |
| Sale of marketable investments | $0 | $574.0K |
| Investment in finance receivables | -$28.5M | -$63.7M |
| Proceeds from sale of finance receivables | $31.7M | $0 |
| Repayment of finance receivables | $56.9M | $53.1M |
| Corporate debt securities principal payments | $21.0K | $27.0K |
| Purchases of property and equipment | -$512.0K | -$138.0K |
| Net cash provided by (used in) investing activities | $68.1M | -$10.1M |
| Net settlement for employee taxes on stock options | -$89.0K | -$43.0K |
| Net payments on from credit facility | -$6.2M | -$6.1M |
| Cash dividends | -$49.1M | $0 |
| Payments on financing costs | -$41.0K | -$50.0K |
| Repurchases of common stock, including fees and expenses | -$3.1M | -$6.0M |
| Net cash used in financing activities | -$58.5M | -$12.2M |
| Net increase in cash and cash equivalents | $36.8M | $691.0K |
| Derecognition of right-of-use assets and operating lease liabilities upon termination of lease | $0 | $82.0K |
| Cash paid for interest | $3.0M | $3.1M |
| Fair value of warrants received with finance receivables | $537.0K | $1.2M |
No quarter-by-quarter statement was filed.
Leadership
Who has led SWK Holdings Corp, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerWinston L. Black Iii. May 19, 2017 to Sep 21, 202212
- Chief executive officerJames Brett Pope May 16, 2012 to Aug 20, 201513
- Chief executive officerJohn Fritzen Nemelka Jun 2, 2010 to May 16, 201214
- Chief executive officerChuck Bay Feb 15, 2006 to Feb 15, 200615
- Chief executive officerMichael S. Fields Sep 12, 2006 to Sep 12, 200616
- PresidentJoe David Staggs Jr. Sep 12, 2022 to now17
- Chief financial officerAdam Rice Jul 8, 2024 to now18
- Chief financial officerYvette M. Heinrichson Oct 5, 2022 to Oct 5, 202219
- Chief financial officerCharles M. Jacobson Sep 6, 2012 to Dec 1, 201420
- Chief financial officerPaul Burgon Jan 13, 2010 to May 16, 201221
- Chief financial officerMichael J. Shannahan Mar 14, 2008 to Mar 14, 200822
Board members and other officers (33)
- Managing DirectorWinston L. Black Iii. May 16, 2012 to Aug 27, 201523
- CAO, VP of FinanceWilliam Feichtmann Jun 1, 2009 to Jul 10, 200924
- Sr. VP, Corporate DevelopmentMark A. Angel May 14, 2007 to Jul 10, 200925
- SVP EngineeringSham Chotai Jun 12, 2007 to Jun 18, 200726
- eVergence Pres. & KANA VPChad Alan Wolf Jun 18, 2007 to Jul 10, 200927
- CTOCharles Hart Isaacs Jun 22, 2007 to Jul 10, 200928
- SVP MarketingMarchai Burris Bruchey Jun 22, 2007 to Jun 22, 200729
- EVP Worldwide Field OperationsDaniel A. Turano Aug 9, 2007 to Jul 10, 200930
- VP, GEN. COUNSEL AND SECRETARYWilliam A. Bose Aug 8, 2006 to Sep 12, 200631
- CHIEF ADMINISTRATIVE OFFICERJay Aaron Jones Sep 12, 2006 to Jul 10, 200932
- Board memberJerry Albright Mar 21, 2023 to now33
- Board memberLaurie L. Dotter Feb 22, 2022 to now34
- Board memberWendy F. Dicicco Feb 22, 2022 to Jan 4, 202335
- Board memberMarcus Edward Pennington May 25, 2021 to Jul 1, 202436
- Board memberAaron G.l. Fletcher Oct 1, 2019 to Jan 12, 202237
- Board memberChristopher W. Haga Sep 16, 2014 to Jan 12, 202238
- Board memberDana Blair Baker Sep 16, 2014 to Jan 12, 202239
- Board memberEdward B. Stead Sep 16, 2014 to Jan 12, 202240
- Board memberWinston L. Black Iii. May 22, 2013 to May 22, 201341
- Board memberBlack Diamond L.p. Double Sep 9, 2013 to May 22, 201742
- Board memberClint Duane Carlson Sep 9, 2013 to May 22, 201742
- Board memberJames Brett Pope May 16, 2012 to Aug 20, 201513
- Board memberMichael Weinberg Jan 7, 2010 to Jan 12, 202243
- Board memberMichael A. Margolis Aug 4, 2010 to Feb 10, 201444
- Board memberChuck Bay Feb 15, 2006 to Feb 15, 200615
- Board memberDixie L. Mills Sep 12, 2006 to Mar 8, 200745
- Board memberJerry R. Batt Sep 12, 2006 to Jul 10, 200946
- Board memberJohn Fritzen Nemelka Sep 12, 2006 to Feb 10, 201447
- Board memberMichael J. Shannahan Sep 12, 2006 to Jul 30, 200748
- Board memberMichael S. Fields Sep 12, 2006 to Sep 12, 200616
- Board memberStephanie Vinella Sep 12, 2006 to Jul 10, 200949
- Board memberWilliam Thaddeus Clifford Sep 12, 2006 to Feb 10, 201450
- General counselWilliam A. Bose Feb 5, 2007 to Jul 10, 200951
Former names
Timeline
- May 19, 2017New chief executive Winston L. Black Iii. becomes CEO12
- May 16, 2012New chief executive James Brett Pope becomes CEO13
- Jun 2, 2010New chief executive John Fritzen Nemelka becomes CEO14
- Sep 12, 2006New chief executive Michael S. Fields becomes CEO16
- Feb 15, 2006New chief executive Chuck Bay becomes CEO15
Filings
261 filings to the SEC since October 2021: 6 annual reports, 13 quarterly reports, 83 major events, 89 insider forms, 13 large holders, 57 other. The latest 20:
- Apr 23, 2026SCHEDULE 13G/A EDGAR
- Apr 16, 202615-12G EDGAR
- Apr 8, 2026EFFECT EDGAR
- Apr 8, 2026EFFECT EDGAR
- Apr 8, 2026SCHEDULE 13D/A EDGAR
- Apr 8, 20264 EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
- Apr 7, 2026S-8 POS EDGAR
The 261 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 9, 2022 | Staggs Joe David JRPRESIDENT | Buy | 2,745 | $16.53 | $45.4K | Form 4 |
| Sep 9, 2022 | Staggs Joe David JRPRESIDENT | Buy | 2,745 | $16.53 | $45.4K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- M3 PARTNERS LPSCHEDULE 13G/A, 4 filings Jul 11, 2022 to Apr 23, 202652
- Carlson Capital, L.P.SCHEDULE 13D/A, 6 filings Nov 12, 2021 to Apr 8, 202653
- CANNELL CAPITAL LLCSC 13G/A, 3 filings Apr 17, 2023 to Nov 14, 202454
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARChuck Bay, Chief executive officer
- 16
- 17SEC EDGARJoe David Staggs Jr., President
- 18SEC EDGARAdam Rice, Chief financial officer
- 19
- 20
- 21SEC EDGARPaul Burgon, Chief financial officer
- 22
- 23
- 24
- 25
- 26SEC EDGARSham Chotai, SVP Engineering
- 27
- 28SEC EDGARCharles Hart Isaacs, CTO
- 29
- 30
- 31
- 32
- 33SEC EDGARJerry Albright, Board member
- 34SEC EDGARLaurie L. Dotter, Board member
- 35SEC EDGARWendy F. Dicicco, Board member
- 36
- 37SEC EDGARAaron G.l. Fletcher, Board member
- 38SEC EDGARChristopher W. Haga, Board member
- 39SEC EDGARDana Blair Baker, Board member
- 40SEC EDGAREdward B. Stead, Board member
- 41SEC EDGARWinston L. Black Iii., Board member
- 42
- 43SEC EDGARMichael Weinberg, Board member
- 44SEC EDGARMichael A. Margolis, Board member
- 45SEC EDGARDixie L. Mills, Board member
- 46SEC EDGARJerry R. Batt, Board member
- 47SEC EDGARJohn Fritzen Nemelka, Board member
- 48SEC EDGARMichael J. Shannahan, Board member
- 49SEC EDGARStephanie Vinella, Board member
- 50
- 51SEC EDGARWilliam A. Bose, General counsel
- 52
- 53
- 54